- Enrollment of pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track for completion in 2023
- Upcoming presentations of 36-month apitegromab data from Phase 2 TOPAZ trial at Cure. | May 9, 2023
CAMBRIDGE, Mass. (BUSINESS WIRE) Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Richard Brudnick, has been appointed to Scholar Rock’s Board of Directors as an.
Scholar Rock Holding (SRRK) Announces the Addition of Richard Brudnick to Its Board of Directors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Operator
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited First Quarter 2021 Earnings Conference Call.
[Operator Instructions]
This conference is being recorded today, May 12, 2021. I would now like to turn the conference call over to Mr. Scott Powell, Executive Vice President of Investor Relations. Please go ahead.
Scott Powell
Executive Vice President, Investor Relations & Chief Financial Officer of Volition America, Inc.
Thank you, and welcome everyone to today s earnings conference call for VolitionRx Limited. This call will cover Volition s financial and operating results for the first quarter of 2021, along with a discussion of our recent activities and key upcoming milestones. Following our prepared remarks, we will open the conference call to a question-and-answer session. On our call today are Mr. Cameron Reynolds, President and Chief Executive Officer; Mr. Terig Hughes, our Chief Financial Officer.
VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Wednesday, May 12, at 8:00 a.m. U.S. Eastern Time
News provided by
Share this article
Strengthened the Company s leadership team to drive commercial focus
Expanded the Company s intellectual property portfolio
Initiated production of product components at scale at the Company s Silver One facility
Published three clinical papers
Continued focus on product launches and licensing in both the human and veterinary spaces
AUSTIN, Texas, May 11, 2021 /PRNewswire/ VolitionRx Limited (NYSE AMERICAN: VNRX) ( Volition ) today announced financial results and a business update for the first quarter ended March 31, 2021. Volition management will host a conference call tomorrow, May 12 at 8:00 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.